argenx SE (ARGX) Stock Forecast, Price Target & Predictions
ARGX Stock Forecast
argenx SE stock forecast is as follows: an average price target of $558.78 (represents a -10.74% downside from ARGX’s last price of $626.03) and a rating consensus of 'Buy', based on 21 wall street analysts offering a 1-year stock forecast.
ARGX Price Target
ARGX Analyst Ratings
Buy
argenx SE Price Target by Analyst
Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
---|---|---|---|---|---|---|
Nov 05, 2024 | George Farmer | Scotiabank | $715.00 | $602.47 | 18.68% | 14.21% |
Oct 10, 2024 | Danielle Brill | Raymond James | $605.00 | $520.52 | 16.23% | -3.36% |
Jul 29, 2024 | Joel Beatty | Robert W. Baird | $515.00 | $495.92 | 3.85% | -17.74% |
Jul 26, 2024 | Douglas Tsao | H.C. Wainwright | $533.00 | $492.06 | 8.32% | -14.86% |
Jul 23, 2024 | Leland Gershell | Oppenheimer | $546.00 | $461.01 | 18.44% | -12.78% |
Jul 22, 2024 | Joon Lee | Truist Financial | $540.00 | $461.01 | 17.13% | -13.74% |
Jul 12, 2024 | Gavin Clark-Gartner | Evercore ISI | $533.00 | $461.72 | 15.44% | -14.86% |
Jun 26, 2024 | Douglas Tsao | H.C. Wainwright | $490.00 | $451.55 | 8.52% | -21.73% |
Jun 24, 2024 | Joon Lee | Truist Financial | $480.00 | $441.15 | 8.81% | -23.33% |
Jun 24, 2024 | George Farmer | Scotiabank | $416.00 | $437.96 | -5.01% | -33.55% |
Jun 24, 2024 | Derek Archila | Wells Fargo | $542.00 | $394.47 | 37.40% | -13.42% |
Jun 24, 2024 | Alex Thompson | Stifel Nicolaus | $500.00 | $436.79 | 14.47% | -20.13% |
May 10, 2024 | Douglas Tsao | H.C. Wainwright | $448.00 | $380.89 | 17.62% | -28.44% |
May 09, 2024 | Derek Archilia | Stifel Nicolaus | $485.00 | $382.55 | 26.78% | -22.53% |
Jan 10, 2023 | H.C. Wainwright | $480.00 | $372.96 | 28.70% | -23.33% | |
Dec 31, 2022 | Stifel Stifel | Stifel Nicolaus | $478.00 | $378.83 | 26.18% | -23.65% |
Jan 20, 2022 | Daan Vandenberk | Kepler Capital | $326.27 | $281.48 | 15.91% | -47.88% |
Jan 07, 2022 | David Nierengarten | Wedbush | $382.00 | $312.58 | 22.21% | -38.98% |
Jan 04, 2022 | James Gordon | J.P. Morgan | $400.00 | $344.00 | 16.28% | -36.11% |
Dec 20, 2021 | Tazeen Ahmad | Bank of America Securities | $383.00 | $337.51 | 13.48% | -38.82% |
Oct 28, 2021 | Yatin Suneja | Guggenheim | $330.00 | $280.83 | 17.51% | -47.29% |
Oct 06, 2021 | Akash Tewari | Jefferies | $362.00 | $293.30 | 23.42% | -42.18% |
Jun 18, 2021 | Laura Sutcliffe | UBS | $390.00 | $318.16 | 22.58% | -37.70% |
argenx SE Price Target by Period
1M | 3M | 12M | |
---|---|---|---|
# Anlaysts | - | 2 | 14 |
Avg Price Target | - | $660.00 | $524.86 |
Last Closing Price | $626.03 | $626.03 | $626.03 |
Upside/Downside | -100.00% | 5.43% | -16.16% |
Analyst Ratings Upgrades/Downgrades
Date | Company | Previous Rating | New Rating | Rating Change |
---|---|---|---|---|
Dec 09, 2024 | Piper Sandler | Overweight | Overweight | Hold |
Nov 22, 2024 | Jefferies | Buy | Buy | Hold |
Nov 11, 2024 | Wolfe Research | Outperform | Upgrade | |
Nov 05, 2024 | Scotiabank | Sector Perform | Outperform | Upgrade |
Nov 01, 2024 | Leerink Partners | Outperform | Outperform | Hold |
Nov 01, 2024 | William Blair | Outperform | Outperform | Upgrade |
Oct 17, 2024 | Wedbush | Underperform | Underperform | Hold |
Oct 17, 2024 | Wells Fargo | Buy | Buy | Hold |
Oct 17, 2024 | Citigroup | Buy | Buy | Hold |
Oct 04, 2024 | Deutsche Bank | Buy | Hold | Downgrade |
Sep 26, 2024 | Wells Fargo | Buy | Buy | Hold |
Sep 25, 2024 | Piper Sandler | Overweight | Overweight | Hold |
Aug 29, 2024 | UBS | Neutral | Neutral | Hold |
Aug 23, 2024 | Wells Fargo | Buy | Buy | Hold |
Aug 06, 2024 | Barclays | Equal-Weight | Overweight | Upgrade |
Jul 29, 2024 | Wells Fargo | Buy | Buy | Hold |
Jul 26, 2024 | Wedbush | Outperform | Outperform | Hold |
Jul 26, 2024 | Oppenheimer | Outperform | Outperform | Hold |
Jul 26, 2024 | Guggenheim | Buy | Buy | Hold |
Jul 26, 2024 | Wells Fargo | Overweight | Overweight | Hold |
Jul 25, 2024 | Deutsche Bank | Buy | Upgrade | |
Jul 23, 2024 | Oppenheimer | Outperform | Upgrade | |
Jul 17, 2024 | H.C. Wainwright | Buy | Buy | Hold |
Jul 12, 2024 | Evercore ISI | Outperform | Outperform | Hold |
Jun 25, 2024 | Barclays | Equal-Weight | Equal-Weight | Hold |
Jun 24, 2024 | Citigroup | Buy | Buy | Hold |
Jun 24, 2024 | Scotiabank | Sector Perform | Sector Perform | Hold |
Jun 24, 2024 | Cowen & Co. | Buy | Buy | Hold |
Jun 24, 2024 | Wells Fargo | Overweight | Overweight | Hold |
Jun 17, 2024 | Piper Sandler | Overweight | Overweight | Hold |
Jun 14, 2024 | H.C. Wainwright | Buy | Buy | Hold |
May 28, 2024 | Barclays | Equal-Weight | Equal-Weight | Hold |
May 10, 2024 | Wells Fargo | Market Outperform | Market Outperform | Hold |
May 10, 2024 | H.C. Wainwright | Buy | Buy | Hold |
Apr 18, 2024 | Wells Fargo | Sector Perform | Sector Perform | Hold |
Mar 26, 2024 | Wells Fargo | Market Outperform | Market Outperform | Hold |
Dec 21, 2023 | Wells Fargo | Overweight | Overweight | Hold |
Nov 30, 2023 | Morgan Stanley | Overweight | Overweight | Hold |
Nov 29, 2023 | Raymond James | Strong Buy | Strong Buy | Hold |
Jan 10, 2023 | Telsey Advisory | Buy | Buy | Hold |
Dec 15, 2022 | Goldman Sachs | Buy | Buy | Hold |
Dec 07, 2022 | William Blair | Outperform | Initialise | |
Oct 28, 2022 | SVB Leerink | Outperform | Outperform | Hold |
Jul 25, 2022 | Piper Sandler | Overweight | Overweight | Hold |
May 03, 2022 | Morgan Stanley | Overweight | Upgrade |
argenx SE Financial Forecast
argenx SE Revenue Forecast
Quarter
Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Mar 23 | Dec 22 | Mar 22 | Mar 21 | Sep 20 | Mar 19 | Mar 18 | Jun 17 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | - | - | - | - | - | - | - | $219.14M | $174.16M | $23.41M | $158.16M | $11.47M | $40.94M | $6.87M | $18.56M |
Avg Forecast | $649.73M | $624.45M | $484.13M | $409.26M | $376.23M | $346.95M | $292.61M | $22.24M | $15.01M | $23.36M | $210.64M | $9.37M | $73.12M | $5.08M | $29.70M |
High Forecast | $723.69M | $685.46M | $530.89M | $448.80M | $412.58M | $354.65M | $320.88M | $26.68M | $18.01M | $28.03M | $252.77M | $11.24M | $87.74M | $6.10M | $35.64M |
Low Forecast | $593.42M | $583.98M | $430.55M | $363.97M | $334.59M | $316.34M | $260.23M | $17.79M | $12.00M | $18.69M | $168.51M | $7.50M | $58.49M | $4.06M | $23.76M |
# Analysts | 8 | 15 | 7 | 6 | 6 | 12 | 10 | 16 | 15 | 7 | 16 | 16 | 12 | 18 | 17 |
Surprise % | - | - | - | - | - | - | - | 9.85% | 11.61% | 1.00% | 0.75% | 1.22% | 0.56% | 1.35% | 0.63% |
Forecast
argenx SE EBITDA Forecast
Quarter
Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Mar 23 | Dec 22 | Mar 22 | Mar 21 | Sep 20 | Mar 19 | Mar 18 | Jun 17 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 8 | 15 | 7 | 6 | 6 | 12 | 10 | 16 | 15 | 7 | 16 | 16 | 12 | 18 | 17 |
EBITDA | - | - | - | - | - | - | - | $-87.16M | $-100.51M | $-221.91M | $-29.25M | $-157.21M | $7.78M | $-21.77M | $-390.75K |
Avg Forecast | $-494.89M | $-475.63M | $-368.75M | $-311.73M | $-205.90M | $-264.27M | $-222.88M | $-217.62M | $-61.43M | $-228.63M | $-38.96M | $-85.62M | $13.90M | $-10.73M | $-625.20K |
High Forecast | $-452.00M | $-444.81M | $-327.94M | $-277.23M | $-164.72M | $-240.95M | $-198.21M | $-174.10M | $-49.15M | $-182.90M | $-31.16M | $-68.50M | $16.68M | $-8.59M | $-500.16K |
Low Forecast | $-551.23M | $-522.11M | $-404.38M | $-341.85M | $-247.08M | $-270.13M | $-244.41M | $-261.15M | $-73.72M | $-274.36M | $-46.75M | $-102.75M | $11.12M | $-12.88M | $-750.24K |
Surprise % | - | - | - | - | - | - | - | 0.40% | 1.64% | 0.97% | 0.75% | 1.84% | 0.56% | 2.03% | 0.63% |
Forecast
argenx SE Net Income Forecast
Quarter
Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Mar 23 | Dec 22 | Mar 22 | Mar 21 | Sep 20 | Mar 19 | Mar 18 | Jun 17 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 8 | 15 | 7 | 6 | 6 | 12 | 10 | 16 | 15 | 7 | 16 | 16 | 12 | 18 | 17 |
Net Income | - | - | - | - | - | - | - | $-28.87M | $-38.61M | $-227.19M | $-40.43M | $-157.66M | $7.58M | $-26.10M | $-387.55K |
Avg Forecast | $114.99M | $74.59M | $5.94M | $-55.15M | $-204.16M | $-74.13M | $-87.12M | $-215.79M | $-61.74M | $-226.70M | $-53.85M | $-85.87M | $13.54M | $-10.73M | $-620.07K |
High Forecast | $170.94M | $146.69M | $6.68M | $-47.21M | $-163.33M | $-38.57M | $-74.59M | $-172.63M | $-49.39M | $-181.36M | $-43.08M | $-68.70M | $16.24M | $-8.59M | $-496.06K |
Low Forecast | $4.35M | $-2.49M | $5.08M | $-62.08M | $-245.00M | $-156.69M | $-98.07M | $-258.95M | $-74.08M | $-272.04M | $-64.62M | $-103.05M | $10.83M | $-12.88M | $-744.09K |
Surprise % | - | - | - | - | - | - | - | 0.13% | 0.63% | 1.00% | 0.75% | 1.84% | 0.56% | 2.43% | 0.63% |
Forecast
argenx SE SG&A Forecast
Quarter
Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Mar 23 | Dec 22 | Mar 22 | Mar 21 | Sep 20 | Mar 19 | Mar 18 | Jun 17 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 8 | 15 | 7 | 6 | 6 | 12 | 10 | 16 | 15 | 7 | 16 | 16 | 12 | 18 | 17 |
SG&A | - | - | - | - | - | - | - | $149.17M | $135.29M | $100.87M | $56.25M | $74.57M | $12.70M | $7.27M | $2.13M |
Avg Forecast | $958.05M | $920.77M | $713.86M | $603.47M | $90.64M | $511.59M | $431.47M | $32.79M | $22.13M | $34.45M | $74.92M | $13.82M | $22.68M | $3.58M | $3.40M |
High Forecast | $1.07B | $1.01B | $782.82M | $661.77M | $108.77M | $522.94M | $473.15M | $39.35M | $26.55M | $41.34M | $89.90M | $16.58M | $27.21M | $4.30M | $4.08M |
Low Forecast | $875.01M | $861.10M | $634.85M | $536.68M | $72.51M | $466.46M | $383.72M | $26.23M | $17.70M | $27.56M | $59.94M | $11.05M | $18.14M | $2.87M | $2.72M |
Surprise % | - | - | - | - | - | - | - | 4.55% | 6.11% | 2.93% | 0.75% | 5.40% | 0.56% | 2.03% | 0.63% |
Forecast
argenx SE EPS Forecast
Quarter
Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Mar 23 | Dec 22 | Mar 22 | Mar 21 | Sep 20 | Mar 19 | Mar 18 | Jun 17 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 8 | 15 | 7 | 6 | 6 | 12 | 10 | 16 | 15 | 7 | 16 | 16 | 12 | 18 | 17 |
EPS | - | - | - | - | - | - | - | $-0.52 | $-0.70 | $-4.36 | $-0.81 | $-3.16 | $0.20 | $-0.81 | $-0.01 |
Avg Forecast | $1.75 | $1.13 | $0.09 | $-0.84 | $-0.72 | $-1.13 | $-1.32 | $1.31 | $1.78 | $1.29 | $-4.16 | $-1.30 | $-1.33 | $-0.19 | $-0.60 |
High Forecast | $2.60 | $2.23 | $0.10 | $-0.72 | $-0.61 | $-0.59 | $-1.13 | $1.48 | $2.00 | $1.29 | $-3.33 | $-1.04 | $-1.06 | $-0.15 | $-0.47 |
Low Forecast | $0.07 | $-0.04 | $0.08 | $-0.94 | $-0.81 | $-2.38 | $-1.49 | $1.12 | $1.52 | $1.29 | $-5.01 | $-1.56 | $-1.58 | $-0.23 | $-0.71 |
Surprise % | - | - | - | - | - | - | - | -0.40% | -0.39% | -3.38% | 0.19% | 2.43% | -0.15% | 4.34% | 0.02% |
Forecast
argenx SE Peer Comparison by Price Target
Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
---|---|---|---|---|---|
TERN | Terns Pharmaceuticals | $6.80 | $18.67 | 174.56% | Buy |
LEGN | Legend Biotech | $34.68 | $89.60 | 158.36% | Buy |
APLS | Apellis Pharmaceuticals | $34.53 | $70.80 | 105.04% | Buy |
AMLX | Amylyx Pharmaceuticals | $4.28 | $8.25 | 92.76% | Buy |
DAWN | Day One Biopharmaceuticals | $12.64 | $24.00 | 89.87% | Buy |
ZLAB | Zai Lab | $26.97 | $50.00 | 85.39% | Buy |
PCVX | Vaxcyte | $89.86 | $148.80 | 65.59% | Buy |
AKRO | Akero Therapeutics | $30.61 | $50.00 | 63.35% | Buy |
ASND | Ascendis Pharma | $140.30 | $211.14 | 50.49% | Buy |
BGNE | BeiGene | $179.06 | $267.33 | 49.30% | Buy |
BPMC | Blueprint Medicines | $96.48 | $122.60 | 27.07% | Buy |
TVTX | Travere Therapeutics | $17.14 | $21.75 | 26.90% | Buy |
ALNY | Alnylam Pharmaceuticals | $246.58 | $310.60 | 25.96% | Buy |
ARGX | argenx SE | $638.33 | $558.78 | -12.46% | Buy |